Evidence map›Paper›PMID 36448244›Full record

ArticleESC heart failure2023

Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry.

Giulia Elena Mandoli, Maria Concetta Pastore, Alberto Giannoni, Giovanni Benfari, Frank Lloyd Dini, Gianmarco Rosa, Nicola Riccardo Pugliese, Claudia Taddei, Michele Correale, Natale Daniele Brunetti and 21 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Left atrial myopathy predicts cardiovascular outcome in hypertension and diabetes.The international journal of cardiovascular imaging · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 20 institutions in 5 countries.

Giulia Elena MandoliDivision of Cardiology, Department of Medical Biotechnologies, University of Siena, Viale Bracci 1, Siena, Italy.
Maria Concetta PastoreDivision of Cardiology, Department of Medical Biotechnologies, University of Siena, Viale Bracci 1, Siena, Italy.ORCID 0000-0002-7223-141X
Alberto GiannoniCardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, Pisa, Italy.
Giovanni BenfariSection of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
Frank Lloyd DiniCentro Medico Santagostino, Milan, Italy.
Gianmarco RosaDepartment of Internal Medicine and Medical Specialities, University of Genoa, Genoa, Italy.
Nicola Riccardo PuglieseDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Claudia TaddeiCardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, Pisa, Italy.
Michele CorrealeCardiology Department, Policlinico Riuniti University Hospital, Foggia, Italy.
Natale Daniele BrunettiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Pietro MazzeoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Erberto CarluccioCardiology and Cardiovascular Pathophysiology-Heart Failure Unit, 'Santa Maria della Misericordia' Hospital, University of Perugia, Perugia, Italy.
Anna MengoniCardiology and Cardiovascular Pathophysiology-Heart Failure Unit, 'Santa Maria della Misericordia' Hospital, University of Perugia, Perugia, Italy.
Andrea Igoren GuaricciUniversity Cardiology Unit, Cardiothoracic Department, Polyclinic University Hospital, Bari, Italy.
Laura PiscitelliUniversity Cardiology Unit, Cardiothoracic Department, Polyclinic University Hospital, Bari, Italy.
Rodolfo CitroCardio-Thoracic-Vascular Department, University Hospital San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
Michele CiccarelliDepartment of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy.
Giuseppina NovoDivision of Cardiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University Hospital Paolo Giaccone, University of Palermo, Palermo, Italy.
Egle CorradoDivision of Cardiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University Hospital Paolo Giaccone, University of Palermo, Palermo, Italy.
Annalisa PasquiniDepartment of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Valentina LoriaDepartment of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Giuseppe De CarliDivision of Cardiology, Department of Medical Biotechnologies, University of Siena, Viale Bracci 1, Siena, Italy.
Anna DegiovanniDepartment of Thoracic, Heart and Vascular Diseases, Maggiore della Carità Hospital, Novara, Italy.
Giuseppe PattiDepartment of Thoracic, Heart and Vascular Diseases, Maggiore della Carità Hospital, Novara, Italy.
Ciro SantoroDepartment of Advanced Biomedical Science, Federico II University Hospital, Naples, Italy.
Luca ModeratoCardiology Department, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
Mariantonietta CicoiraSection of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
Marco CanepaCardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, IRCCS Italian Cardiovascular Network, Genoa, Italy.
Alessandro MalagoliDivision of Cardiology, Nephro-Cardiovascular Department, Baggiovara Hospital, University of Modena and Reggio Emilia, Modena, Italy.
Michele EmdinCardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, Pisa, Italy.
Matteo CameliDivision of Cardiology, Department of Medical Biotechnologies, University of Siena, Viale Bracci 1, Siena, Italy.
University of Siena · ITDepartment of Health · ESPolyclinic General Hospital · GRScuola Superiore Sant'Anna · ITUniversità Cattolica del Sacro Cuore · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Foggia · ITUniversity of Perugia · ITUniversity of Verona · ITCentro Diagnostico Italiano · ITFederico II University Hospital · ITFondazione Toscana Gabriele Monasterio · ITGuglielmo da Saliceto Hospital · ITOspedale Policlinico San Martino · ITOspedali Riuniti di Foggia · ITOspedali Riuniti San Giovanni di Dio e Ruggi d'Aragona · ITUniversity of Genoa · ITUniversity of Modena and Reggio Emilia · ITUniversity of Pisa · ITUniversity of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsSacubitril/valsartan has changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left ventricular (LV) reverse remodelling (LVRR). The aim of this multicenter study was to identify echocardiographic predictors of LVRR after sacubitril/valsartan administration. METHODS AND

resultsPatients with HFrEF requiring therapy with sacubitril/valsartan from 13 Italian centres were included. Echocardiographic parameters including LV global longitudinal strain (GLS) and global peak atrial longitudinal strain by speckle tracking echocardiography were measured to find the predictors of LVRR [= LV end-systolic volume reduction ≥10% and ejection fraction (LVEF) improvement ≥10% at follow-up] at 6 month follow-up as the primary endpoint. Changes in symptoms [New York Heart Association (NYHA) class] and neurohormonal activations [N-terminal pro-brain natriuretic peptide (NT-proBNP)] were also evaluated as secondary endpoints; 341 patients (excluding patients with poor acoustic windows and missing data) were analysed (mean age: 65 ± 10 years; 18% female, median LVEF 30% [inter-quartile range: 25-34]). At 6 month follow-up, 82 (24%) patients showed early complete response (LVRR and LVEF ≥ 35%), 55 (16%) early incomplete response (LVRR and LVEF < 35%), and 204 (60%) no response (no LVRR and LVEF < 35%). Non-ischaemic aetiology, a lower left atrial volume index, and a higher GLS were all independent predictors of LVRR at multivariable logistic analysis (all P < 0.01). A baseline GLS < -9.3% was significantly associated with early response (area under the curve 0.75, P < 0.0001). Left atrial strain was the best predictor of positive changes in NYHA class and NT-proBNP (all P < 0.05).

conclusionsSpeckle tracking echocardiography parameters at baseline could be useful to predict LVRR and clinical response to sacubitril-valsartan and could be used as a guide for treatment in patients with HFrEF.

Indexed as

Atrial FibrillationHeart FailureVentricular Dysfunction, LeftAgedAminobutyratesBiphenyl CompoundsDrug CombinationsEchocardiographyFemaleHumansMaleMiddle AgedStroke VolumeTetrazolesValsartanAminobutyratesBiphenyl CompoundsDrug Combinationssacubitrilsacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanBiomarkersCardiovascular diseaseEchocardiographyHeart failureImagingRemodellingSacubitril/valsartanSpeckle trackingUltrasound

Identifiers

PMID36448244
PMCPMC10053272
OpenAlexW4310457913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.